Impact of the 10-valent pneumococcal conjugate vaccine on the incidence of respiratory and ENT diseases and antibiotic consumption in children under 5 years of age in Barnaul | CMAC

Impact of the 10-valent pneumococcal conjugate vaccine on the incidence of respiratory and ENT diseases and antibiotic consumption in children under 5 years of age in Barnaul

Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(2):156-160

​ Kozyanova Yu.A., Safyanova T.V.
10.36488/cmac.2018.2.156-160
S. pneumoniae pneumococcal conjugated vaccine morbidity antibiotic consumption
Section
Personal Experience
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(2):156-160

Objective.

To evaluate epidemiological efficacy of the 10-valent pneumococcal conjugated vaccine (PCV10) as assessed by the number of episodes of respiratory tract and ENT diseases and by the number of antibiotic courses prescribed for those diseases in children under 5 years of age in Barnaul.

Materials and Methods.

At the end of 2016, a total of 312 children under 60 months of age were enrolled into a retrospective cohort epidemiological study and divided into 2 cohorts (156 children each). The first cohort consisted of the children who received at least 2 doses of PCV10; the second cohort consisted of the age-matched children who didn’t receive any pneumococcal vaccines. Reporting and assessment of any episodes of acute respiratory diseases, rhinitis, tonsillitis, adenoiditis, pharyngitis, tracheitis, bronchitis, pneumonia, acute otitis media, and sinusitis as well as any antibiotic courses administered for those conditions were performed in the both cohorts by a review of the children’s medical records. The quartile method was used to assess data distribution. The differences in the incidence of respiratory tract and ENT diseases and antibiotic consumption between the two cohorts were assessed using chi-square test.

Results.

Comparative analysis of morbidity and incidence of antibiotic prescriptions showed significant differences between vaccinated and non-vaccinated children (p<0.05). The PCV10 efficacy as assessed by reduction in the number of antibiotic courses was 52.7% (95% CI: 43.7-61.6) and reduction in the incidence of the respiratory tract and ENT diseases was 34.1% (95% CI: 31.1-37.0).

Conclusions.

The use of PCV10 in children is associated with reduced incidence of respiratory tract and ENT diseases and reduced antibiotic consumption administered for those diseases.

Yuliya A. Kozyanova

Altai State Medical University, Barnaul, Russia

Safyanova T.V.

Altai State Medical University, Barnaul, Russia

  • 1. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec. 2007;82(12):93-104.
  • 2. Recommendations of extended expert council, calling by union of pediatricians of Russia: burden of pneumococcal diseases in Russia. Voprosy sovremennoj pediatrii. 2009;8(2):104-108. Russian.
  • 3. Baranov A.A, Briko N.I., Namazova-Baranova L.S., Ryapis L.A. Streptococci and pneumococci. M.: Feniks, 2013. 301 p. Russian.
  • 4. Stratchounski L.S., Bogomilski M.R. Antibacterial therapy of acute otitis media in children. Detskij doktor. 2000;22:32-33. Russian.
  • 5. Safianova T.V. Several peculiarities of the incidence rate of out-ofhospital pneumonia and acute otitis media in the Altai Territory. Medial’. 2014;3(13):78-80. Russian.
  • 6. Kozyanova Yu.A., Safianova T.V. Several epidemiological peculiarities of outhospital pneumonia in the Altai Territory. Medicinskij al’manah. 2016;3(43):108-111. Russian.
  • 7. Kosenko I.M. Antibacterial therapy of community-acquired respiratory and ENT-infections: new potentials for overcoming resistance. Farmateka. 2011;(18):15-20. Russian.
  • 8. Mayanskiy N.A., Alyabieva N.M., Lazareva M.A., et al. Antimicorbial Susceptibility, Clonal and Serotype Diversity of Streptococcus pneumoniae Isolated from Children with Acute Otitis Media in Moscow. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2016;18(2):84-92. Russian.
  • 9. Yakovlev S.V., Sidorenko S.V., Rafalsky V.V., Spichak T.V., eds. Strategy and tactics of rational use of antimicrobial agents in outpatient practice: Russian practical recommendations. M.: Izdatel’stvo Presto, 2014. 121 p. Russian.
  • 10. Tatochenko V.K., Bakradze M.D., Khokhlova T.A., Rogova O.A. Rational antibiotic therapy of respiratory infections. Medicinskij sovet. 2014;(1):62-67. Russian.
  • 11. Mironov K.O., Platonov A.E., Kozlov R.S. PCR-based Identification and Serotyping of Russian Streptococcus pneumoniae Strains. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2011;13(4):304-313. Russian.
  • 12. Kozlov R.S., Chagaryan А.N., Kozlova L.V., Muravyev А.А. Serological Characteristics and Antimicrobial Susceptibility of Streptococcus pneumoniae Isolated from Children 0-5 Years of Age in Different Regions of Russia. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2011;13(2):177-187. Russian.
  • 13. Inostroza J., Trucco O., Prado V., et al. Capsular serotype and antibiotic resistance of Streptococcus pneumoniae isolates in two Chilean cities. Clin Diagn Lab Immunol. 1998;5(2):176-180.
  • 14. Order of the Ministry of Health of the Russian Federation of March 21, 2014 N 125н “On approval of the national calendar of preventive vaccinations and the calendar of preventive vaccinations for epidemiological indications.” Available at: http://base.garant. ru/70647158/#ixzz4yUyCFejY. Russian.
  • 15. Palmu A.A., Jokinen J., Nieminen H., et al. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial. Lancet Infect Dis. 2014;14:205-212.
  • 16. Palmu A.A., Rinta-Kokko H., Nohynek H., et al. Impact of tenvalent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study. PLoS One. 2017;12(3):e0172690.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared